CT-derived skeletal muscle change before immunotherapy predicts survival of advanced gastric cancer: associations with inflammatory markers and liver lipid metabolism
International Journal of Clinical Oncology · 2024
DOI: 10.1007/s10147-024-02551-x ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Koichi Hayano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Frontier Surgery, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan. k-hayano@chiba-u.jp. Hauptthemen laut MEDLINE: Stomach Neoplasms, Tomography, X-Ray Computed, Lipid Metabolism, Liver. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Skeletal muscle (SM) is a key factor in cancer treatment. However, it is unclear whether pretreatment SM change affects the outcome of immune checkpoint inhibitors (ICIs) therapy in gastric cancer (GC).
Methods
Advanced GCs treated with ICIs were retrospectively investigated. SM evaluated by psoas muscle area at the third lumbar vertebra was measured on CT acquired within 1 month from the start of ICIs therapy (CT-1), and on CT acquired 2.8 ± 0.84 months before CT-1. Monthly change rate of SM (MCR-SM) was defined as the change rate of SMs between those two CTs divided by the period between those CTs (month). Monthly change rate of body weight (MCR-BW) during the same period was also calculated. They were compared with disease-specific survival (DSS) and progression-free survival (PFS). MCR-SM was compared with pretreatment markers including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), C-reactive protein (CRP), and liver-to-spleen CT attenuation ratio (LSR) as a marker of liver lipid metabolism.
Results
This study enrolled eighty-three GC patients. MCR-SM significantly correlated with DSS and PFS ( P < 0.0001, 0.001, respectively), whereas MCR-BW did not. Kaplan–Meier analyses demonstrated that higher MCR-SM (MCR-SM ≥ −0.7185%) significantly associated with better DSS and PFS ( P = 0.0002, 0.03, respectively). Patients with positive MCR-SM showed significantly lower NLR, MLR, and CRP than those with negative ( P = 0.01, 0.006, 0.003, respectively). MCR-SM showed a significant positive correlation with LSR ( P = 0.007, R = 0.30).
Conclusions
Pretreatment SM loss, associated with high systemic inflammation and hepatic fat accumulation, related to poor outcome of ICIs therapy in GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Frontier Surgery, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan. k-hayano@chiba-u.jp.
- Department of Frontier Surgery, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan.
Zitieren
APA
Hayano, K., Ohira, G., Matsumoto, Y., Kurata, Y., Otsuka, R., Hirata, A., Toyozumi, T., Murakami, K., Uesato, M., & Matsubara, H. (2024). CT-derived skeletal muscle change before immunotherapy predicts survival of advanced gastric cancer: associations with inflammatory markers and liver lipid metabolism. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02551-x
Vancouver
Hayano K, Ohira G, Matsumoto Y, Kurata Y, Otsuka R, Hirata A, et al. CT-derived skeletal muscle change before immunotherapy predicts survival of advanced gastric cancer: associations with inflammatory markers and liver lipid metabolism. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02551-x
BibTeX
@article{Hayano2024,
author = {Hayano, Koichi and Ohira, Gaku and Matsumoto, Yasunori and Kurata, Yoshihiro and Otsuka, Ryota and Hirata, Atsushi and Toyozumi, Takeshi and Murakami, Kentaro and Uesato, Masaya and Matsubara, Hisahiro},
title = {CT-derived skeletal muscle change before immunotherapy predicts survival of advanced gastric cancer: associations with inflammatory markers and liver lipid metabolism},
journal = {International Journal of Clinical Oncology},
year = {2024},
doi = {10.1007/s10147-024-02551-x}
}
EUVIMED